Cytosorbents (NASDAQ: CTSO) reported Q3 EPS of ($0.10), $0.04 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $5.7 million versus the consensus estimate of $5.79 million.

GUIDANCE:

We expect Q4 2018 product sales to exceed Q3 2018 product sales.

For earnings history and earnings-related data on Cytosorbents (CTSO) click here.